News
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants
Jaguar Health, Inc. strengthens balance sheet by restructuring debt and royalty obligations. Sharp focus on global development program for crofelemer. CEO Lisa Conte prioritizes capitalization -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1
Jaguar Health, Inc. receives $16M non-dilutive capital from U.S. license agreement with Future Pak for crofelemer drugs. Strategy focuses on rare-disease intestinal failure indications -
-
-
COMMUNIQUÉ DE PRESSE
Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health's Special One-time Stock Dividend
Jaguar Health issues a Special Stock Dividend to provide dilution protection to shareholders as part of debt restructuring efforts. Preferred Stock payment date on March 4, 2026 -
-
